9/27/04

1,pw	
------	--

	0	17	E	$\stackrel{>}{>}$
/ P.	SEP 2	2 4	2004	
(E	& TRA	DE	ARK	

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTA	L
FORM	

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

•	1	1
Application Number	10/769,157	
Filing Date	1/29/2004	
First Named Inventor	Joshua D. Rabinowitz	
Art Unit	Not yet known	
Examiner Name	To be assigned	
Attorney Docket Number	00037.09CON	

	ENCLOSURES (check all that apply)
Fee Transmittal Form	Drawing(s)	After Allowance communication to Group
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert a Provisional Application	Proprietary Information
Affidavits/declaration(s) Power of Attorney, Revocation Change of Correspondence		Status Letter
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):
Express Abandonment Request	Request for Refund	
Information Disclosure Statement	CD, Number of CD(s)	
Certified Copy of Priority Document(s)	Remarks	<u> </u>
Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Info. Discl. Statemetn (2 pp.) Form 1449 (3 copies, 8 pages each) Copy of : Areferences / 8/ Return Postcard	
SIGNATU	RE OF APPLICANT, ATTORNEY, OR AGEN	IT
Firm or Individual name ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Customer Number 37485 Customer Number 37485		
Signature Muni	Strick	
Date SEP; 2	4 2004	
C	EDTIFICATE OF TRANSMISSION/MAIL	INC

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name Elaine C. Stracker

Signature Date SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450

Efaine C. Stracker

PATENT

Attorney's Docket No.: 00037.09CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/769,157

Filed:

1/29/2004

Title

DELIVERY OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR

TRIAZOLAM THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

SEP.	24	2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

rom PIO	1449
INFOR	MATION DISCLOSURE CITATION AN APPLICATION
OIPE	AIN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	00037.09CON	١.
----------------	-------------	----

Application Number: 10/769,157

Applicant:

Joshua D. RABINOWITZ et al.

Filing Date: 01/29/2004

Group Art Unit: Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
······	3.	10/21/1980	4,229,447	Porter			
	4.	04/02/1985	4,508,726	Coleman			
	5.	05/13/1986	4,588,721	Mahan			
	6.	07/28/1987	4,683,231	Glassman			
	7.	09/05/1989	4,863,720	Burghart et al.			
	8.	01/23/1990	4,895,719	Radhakrishnun et al.			
	9.	09/17/1991	5,049,389	Radhakrishnun			
	10.	03/31/1992	5,099,861	Clearman et al.			
	11.	11/24/1992	5,166,202	Schweizer	1		
•	12.	08/31/1993	5,240,922	O'Neill	1		
	13.	02/14/1995	5,388,574	Ingebrethsen			•
	14.	10/10/1995	5,457,100	Daniel			
	15.	08/06/1996	5,543,434	Weg			
	16.	08/13/1996	5,544,646	Lloyd et al.		· .	
	17.	08/12/1997	5,655,523	Hodson et al.			
	18.	12/09/1997	5,694,919	Rubsamen et al.			
	19.	04/07/1998	5,735,263	Rubsamen et al.		,	
	20.	04/14/1998	5,738,865	Baichwal et al.		٠	
	21.	06/02/1998	5,758,637	Ivri et al.			
	22.	06/16/1998	5,767,117	Moskowitz			
-	23.	06/29/1999	5,915,378	Lloyd et al.			
•	24.	08/10/1999	5,934,272	Lloyd et al.			
	25.	09/28/1999	5,957,124	Lloyd et al.			
	26.	10/05/1999	5,960,792	Lloyd et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-14	49		Docket Number: 00037.09CON Application Number: 10/76	9,157
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant: Joshua D. RABINOWITZ et al.	
	(Use several sheets if n	ecessary)	Filing Date: 01/29/2004 Group Art Unit: Not Yet Ki	nown
	_			
27	11/30/1999	5,993,805	Sutton et al.	
28	 	6,041,777	Faithfull et al.	<u> </u>
29		6,048,857	Ellinwood, Jr. et al.	
30		6,051,566	Bianco	
31		Re. 36,744	Goldberg	
32		6,095,153	Kessler et al.	
33		6,102,036	Slutsky et al.	
34	. 10/17/2000	6,133,327	Kimura et al.	
· 35	. 10/31/2000	6,140,323	Ellinwood, Jr. et al.	
36	. 06/05/2001	6,241,969	Saidi et al.	
37	. 07/03/2001	6,255,334	Sands	
38	. 01/14/2003	6,506,762	Horvath et al.	
39	. 02/04/2003	6,514,482	Bartus et al.	
40	. 07/15/2003	6,591,839	Meyer et al.	
41	. 09/06/2001	US 2001/0020147	Staniforth et al.	
42	. 03/28/2002	US 2002/0037828	Wilson et al.	
43	. 05/16/2002	US 2002/0058009	Bartus et al.	
44	. 07/04/2002	US 2002/0086852	Cantor	
45	. 08/22/2002	US 2002/0112723	Schuster et al.	
46	. 11/28/2002	US 2002/0176841	Barker et al.	
47	. 01/02/2003	US 2003/0004142	Prior et al.	
48	. 02/13/2003	US2003/0032638	Kim et al.	
		10146086	,	
RELA	TED ALEXZA		IVERY CORPORATION PATENT DOCUMENTS	}
49.	08/04/2003	10/633,876	Hale et al.	
50.	08/04/2003	10/633,877	Hale et al.	
51.	12/30/2003	10/749,537	Rabinowitz et al.	
52.	12/30/2003	10/749,539	Rabinowitz et al.	
53.	01/27/2004	10/766,149	Rabinowitz et al.	
54.	01/27/2004	10/766,279	Rabinowitz et al.	
EXAMINER	•		DATE CONSIDERED:	
EXAMINER: conformance a	Initial if citation considered. Inc	dered, whether or not the cital	ation conforms with MPEP 609. Draw a line through the citation if n h next communication to applicant.	ot in

Form PT	O-14	49		Docket Number: 00037.09CON Application Number: 10/769,157
INFO		ATION DISCLOS IN AN APPLICA	SURE CITATION ATION	Applicant: Joshua D. RABINOWITZ et al.
		(Use several sheets if n	ecessary)	Filing Date: 01/29/2004 Group Art Unit: Not Yet Known
			10 3 46 9 54	
			10437643	
	55.	01/27/2004	10/766,566	Rabinowitz et al.
	56.	01/27/2004	10/766,574	Rabinowitz et al.
	57.	01/27/2004	10/766,634	Rabinowitz et al.
	58.	01/27/2004	10/766,647	Rabinowitz et al.
	59.	01/28/2004	10/767,115	Rabinowitz et al.
	60.	01/29/2004	10/768,205	Rabinowitz et al.
	61.	01/29/2004	10/768,220	Rabinowitz et al.
	62.	01/29/2004	10/768,281	Rabinowitz et al.
	63.	01/29/2004	10/768,293	Rabinowitz et al.
	64.	01/30/2004	10/769,046	Rabinowitz et al.
	65.	01/30/2004	10/769,051	Rabinowitz et al.
	66.	01/29/2004	10/769,197	Rabinowitz et al.
	67.	02/09/2004	10/775,583	Rabinowitz et al.
	68.	02/09/2004	10/775,586	Rabinowitz et al.
	69.	03/03/2004	10/791,915	Hale et al.
	70.	03/03/2004	10/792,001	Rabinowitz et al.
	71.	03/03/2004	10/792,012	Hale et al.
	72.	03/03/2004	10/792,013	Rabinowitz et al.
	73.	03/03/2004	10/792,096	Hale et al.
	74.	03/03/2004	10/792,239	Hale et al.
,	75.	03/31/2004	10/813,721	Rabinowitz et al.
	76.	03/31/2004	✓ 10/813,722 ✓	Rabinowitz et al.
	77.	03/31/2004	V 10/814,690 /	Rabinowitz et al.
	78.	03/31/2004	√ 10/814,998 <i>/</i>	Rabinowitz et al.
	79.	04/01/2004	√10/815,527 ✓	Rabinowitz et al.
	80.	04/01/2004	√10/816,407 _/	Rabinowitz et al.
	81.	04/01/2004	10/816,492	Rabinowitz et al.
	82.	04/01/2004	√10/816,567 /	Rabinowitz et al.
	83.	08/04/2004	10/912,462	Hale et al.
	84.	01/23/2003	US 2003/0015196	Hodges et al.
		1		press Mail EV 428 189404US
EXAM	INER:			DATE CONSIDERED:
EXAMI conform	NER: I	Initial if citation considered. Incl	lered, whether or not the citude a copy of this form with	ation conforms with MPEP 609. Draw a line through the citation if not in h next communication to applicant.

Form PTO-1449 Application Number: 10/769,157 Docket Number: 00037.09CON INFORMATION DISCLOSURE CITATION Applicant: Joshua D. RABINOWITZ et al. IN AN APPLICATION (Use several sheets if necessary) Group Art Unit: Not Yet Known Filing Date: 01/29/2004 85. l 04/03/2003 US 2003/0062042 Wensley et al. 86. 11/13/2003 US 2003/0209240 Hale et al. 87. 01/02/2003 US 2003/0000518 Rabinowitz et al. 88. 01/09/2003 US 2003/0005924 Rabinowitz et al. 89. 01/09/2003 US 2003/0005925 Hale et al. 90. | 01/09/2003 US 2003/0007933 Rabinowitz et al. 91. 01/09/2003 US 2003/0007934 Rabinowitz et al. 92. 01/16/2003 US 2003/0012737 Rabinowitz et al. 93. 01/16/2003 US 2003/0012738 Rabinowitz et al. 94. 1/16/2003 US 2003/0012740 Rabinowitz et al. 95. 01/23/2003 US 2003/0015189 Rabinowitz et al. 01/23/2003 US 2003/0015190 96. Rabinowitz et al. 97. 01/23/2003 US-2003/0017114 Rabinowitz et al. 01/23/2003 98. US 2003/0017115 Rabinowitz et al. 99. 01/23/2003 US 2003/0017116 Rabinowitz et al. 100. 01/23/2003 US 2003/0017117 Rabinowitz et al. 01/23/2003 101. US 2003/0017118 Rabinowitz et al. 102. 01/23/2003 US 2003/0017119 Rabinowitz et al. 103. 01/23/2003 US 2003/0017120 Rabinowitz et al. 104. 1/30/2003 US 2003/0021753 Rabinowitz et al. 105. 01/30/2003 US 2003/0021754 Rabinowitz et al. 106. 01/30/2003 US 2003/0021755 Hale et al. 107. 02/20/2003 US 2003/0035776 Hodges et al. 108. 05/15/2003 US 2003/0091511 Rabinowitz et al. 109. 05/27/2004 US 2004/010148 Hale et al. 110. 07/31/2003 US 2003/0138382 **Rabinowitz** 111. 11/06/2003 US 2003/0206869 Rabinowitz et al. 112. 01/15/2004 US 2004/0009128. Rabinowitz et al. 113. 05/20/2004 US 2004/0096402 Hodges et al. 114. 05/27/2004 US 2004/0099269 Hale et al. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 5 of 8 Form PTO-1449 Docket Number: 00037.09CON Application Number: 10/769,157 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION (Use several sheets if necessary) Filing Date: 01/29/2004 Group Art Unit: Not Yet Known 06/03/2004 US 2004/0105818 115. Hale et al. 116. 06/03/2004 US 2004/0105819 Hale et al. 117. 07/01/2004 US 2004/0126326 Rabinowitz et al. 118. 07/01/2004 US 2004/0126327 Rabinowitz et al. US 2004/0126328 119. 07/01/2004 Rabinowitz et al. 120. 07/01/2004 US 2004/0126329 Rabinowitz et al. 121. 07/01/2004 US 2004/0127481 Rabinowitz et al. 122. 07/01/2004 US 2004/0127490 Rabinowitz et al. 123. 08/12/2004 US 2004/0156788 Rabinowitz et al. 124. 08/12/2004 US 2004/0156789 Rabinowitz et al. 125. 8/12/2004 US 2004/0156790 Rabinowitz et al. 126. 08/12/2004 US 2004/0156791 Rabinowitz et al. FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Country Class Subclass Translation **Initials** No. YES NO 127. 01/02/1996 CA 2,152,684 Canada 128. 03/14/1990 EP 0 358 114 Europe EP 1 080 720 129. 07/03/2001 Europe EP 0 606 486 130. 08/29/2001 Europe 131. 03/22/1990 WO 90/02737 **WIPO** 132. 04/11/1996 WO 96/09846 **WIPO** 133. 05/09/1996 WO 96/13161 **WIPO** 05/09/1996 WO 96/13290 134. **WIPO** 135. 05/09/1996 WO 96/13291 **WIPO** 136. 05/09/1996 WO 96/13292 **WIPO** 137. 10/03/1996 WO 96/30068 **WIPO** 138. 08/07/1997 WO 97/27804 **WIPO**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

DATE CONSIDERED:

PTO/SB/ 08 (2-92)

EXAMINER:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) 139. 05/28/1998 WO 98/22170 WIPO 140. 07/23/1998 WO 98/31346 WIPO 141. 08/27/1998 WO 98/36651 WIPO 142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO 145. 01/06/2000 WO 00/00215 WIPO 145. 01/06/2000 WO 00/00215 WIPO 146. WIPO 147. WIPO WIPO	,157			
139. 05/28/1998 WO 98/22170 WIPO 140. 07/23/1998 WO 98/31346 WIPO 141. 08/27/1998 WO 98/36651 WIPO 142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO				
140. 07/23/1998 WO 98/31346 WIPO 141. 08/27/1998 WO 98/36651 WIPO 142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO	own			
140. 07/23/1998 WO 98/31346 WIPO 141. 08/27/1998 WO 98/36651 WIPO 142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO				
140. 07/23/1998 WO 98/31346 WIPO 141. 08/27/1998 WO 98/36651 WIPO 142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO				
141. 08/27/1998 WO 98/36651 WIPO 142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO				
142. 04/08/1999 WO 99/16419 WIPO 143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO				
143. 12/16/1999 WO 99/64094 WIPO 144. 01/06/2000 WO 00/00176 WIPO				
144. 01/06/2000 WO 00/00176 WIPO				
145 01/06/2000 WO 00/00215 WIPO				
146. 05/18/2000 WO 00/27363 WIPO				
147. 05/25/2000 WO 00/29053 WIPO				
148. 09/17/2000 WO 00/47203 WIPO				
149. 11/02/2000 WO 00/64940 WIPO				
150. 11/09/2000 WO 00/66084 WIPO				
151. 11/09/2000 WO 00/66206 WIPO				
152. 12/21/2000 WO 00/76673 WIPO				
153. 01/25/2001 WO 01/05459 WIPO				
154. 03/28/2002 WO 02/24158 WIPO				
155. 03/28/2002 WO 02/24158 WIPO				
OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)				
Examiner Ref. Title Initials No.				
156. Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative I Relief," <i>Annual Surg.</i> 195(6):700-705.	Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," Annual Surg. 195(6):700-705.			
157. Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physic effects," <i>Psychopharmacology</i> (Berl). 102:443-450.	ological			
158. Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Size," Z. Erkrank. 166:13-24.	Particle			
Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Num Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.	erical			
Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Phy 32(5):591-600.	siology			
EXAMINER: DATE CONSIDERED:				
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if no conformance and not considered. Include a copy of this form with next communication to applicant.	t in			
PTO/SB/ 08 (2-92) Patent and Trademark Office; U.S. DEPARTMENT OF CO.	MERCE			

Form PTO-1449		Docket Number: 00037.09CON	Application Number: 10/769,157
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Joshua D. RABINOWITZ et al.	
(Use several sheets if necessary)		Filing Date: 01/29/2004	Group Art Unit: Not Yet Known
161.	Dershwitz, M., M.D., et al. (Septembe versus Intravenous Morphine in Health		
162.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.		
163.	Gonda,I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, <u>The Lung: Scientific Foundations</u> . Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.		
164.	Hatsukami D, et al. (May 1990) "A method for delivery of precise doses of smoked cocaine-base to humans." <i>Pharmacology Biochemistry & Behavior</i> . 36(1):1-7.		
165.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.		
166.	Huizer, H., "Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking." Pharmaceutisch Weekblad Scientific Edition (1987). 9(4):203-211.		
167.	Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.		
168.	Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.		
169.	Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," <i>Journal of Analytical Toxicology</i> 13:158-162.		
170.	Mattox, A.J. and Carroll, M.E., (1996). "Smoked heroin self-administration in rhesus monkeys," <i>Psychopharmacology</i> , 125:195-201.		
171.	McCORMICK, A.S.M., et al., "Bronchospasm During Inhalation of Nebulized Midazolam," BRITISH JOURNAL OF ANAESTHESIA, vol. 80(4), April 1988, pgs. 564-565.		
172.	Meng, Y. et al. "Inhalation Studies With Drugs of Abuse, " NIDA Research Monograph, (1997) 173:201-224.		
173.	Meng, Y., et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure," <i>Drug and Alcohol Dependence</i> . 53:111-120.		
174.	Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "DELIVERY OF BENZODIAZEPINES THROUGH AN INHALATION ROUTE"		
175.	Pankow, J.F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form Through the Action of Gaseous Ammonia," <i>Envron. Sci. Technol.</i> 31:2428-2433.		
176.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke. pp. 1-8.		
177.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.		
EXAMINER:		DATE CONSIDERED:	
	al if citation considered, whether or not the citation to considered. Include a copy of this form with n		ine through the citation if not in

PTO/SB/08 (2-92) Sheet 8 of 8

Form PTO-1449	Docket Number: 00037.09CON	Application Number: 10/769,157	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.		
(Use several sheets if necessary)	Filing Date: 01/29/2004	Group Art Unit: Not Yet Known	
Inhalation Efficiency and Pyrolysis I 32(5):1271-1280.	Sekine, H. and Nakahara, Y. (1987). "Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamphetamine," <i>Journal of Forensic Science</i> 32(5):1271-1280.		
179. Vapotronics, Inc. (1998) located at <u>h</u> June 5, 2000).	Vapotronics, Inc. (1998) located at http://www.vapotronics.com.au/banner.htm , 11 pages, (visited on June 5, 2000).		
180. Ward, M.E. MD, et al. (December 19 Administration from a Novel Aerosci 62(6):596-609.	Ward, M.E. MD, et al. (December1997). "Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System," <i>Clinical Pharmacology & Therapeutics</i> 62(6):596-609.		
Pyrolyzate, Methylecgonidine, and I	Wood, R.W. et al. (1996). "Generation of Stable Test Atmospheres of Cocaine Base and Its Pyrolyzate, Methylecgonidine, and Demonstration of Their Biological Activity." <i>Pharmacology Biochemistry & Behavior</i> . 55(2):237-248.		
		•	
	,		
		•	
·			
	•		
•			
	•		
·			
•			
·			
EXAMINER:	DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.